The Chinese pharmaceutical regulator has approved the drug for the treatment of so-called tenosynovial giant cell tumors where surgery is not an option, the company announced on Monday. Pimicotinib, developed in collaboration with Chinese company Abbisko Therapeutics, is now the first drug to receive approval in China for the treatment of these tumors.
This concerns a rare disease in which growths form in tendon sheaths or joints, often affecting younger patients. If left untreated, these tumors can cause severe damage to joints, tendons, and bones. The approval process is also underway in Europe and the United States.
(Reporting by Christina Amann, edited by Sabine Wollrab. For inquiries, please contact our editorial team at Berlin.Newsroom@thomsonreuters.com (for politics and economy) or Frankfurt.Newsroom@thomsonreuters.com (for companies and markets)
